Search

Preclinical studies showed synergic anti-tumor activity of Rituximab and Fludarabin. Comparison of efficacy of FC with FCR regimens administered in first line therapy and their influence on disease-free and overall survival in patients with B-cell lymphocytic leukemia were the main goals of this retrospective study. It has been demonstrated that inclusion of Rituximab into the FC regimen improves outcome of patients with B-cell lymphocytic leukemia without significant increase of toxicity.

New guidelines on diagnosis and treatment of a primary immune thrombocytopenia (ITP) in children and adults, on the basis of modern pathogenesis conceptions and considering possibilities of hematological practice in Russia are presented. Guidelines are based on a consensus of international and Russian experts on ITP. Diagnostic features of ITP are noted and various I, II and III lines treatment, including new effective medical products which have recently appeared in Russia, in particular, trombopoietin receptor agonists (romiplostim, eltrombopag), considerably expanded conservative treatment possibilities are offered. The presented guidelines can help hematologists to develop individual schedule for each given patients with ITP and to improve patients quality of life.

The estimation of immediate and long-term results after splenectomy depending on indications and contra-indications for 18 primary myelofibrosis (PMF) patients was shown. The reduction of intra- and postoperative complications in PMF patients was noted if the operation wasperformed under strict indications and also with prophylactic heparin therapy. Life expectancy is extended after splenectomy during subsequentrelevant specific treatment.

Primary myelofibrosis (PMF) is one of the diseases that cannot be cured using modern methods of conservative therapy. Therefore, treatment aimed at reducing PMF severity and improving patient’s quality of life. In this article, a comparative analysis of treatment response and quality of life depending on therapy using was shown. Partial remission rate at approximately the same level after α-interferon treatment (55.3 %) and after cytotoxic drug (48.8 %) was observed. Significant improvement in quality of life during α-interferon treatment was revealed.

Literature data of idiopathic myelofibrosis are presented: classification, diagnostic criteria, morphological and molecular features. Particular attention is given to therapy of various clinical forms of primary myelofibrosis.

Primary immune thrombocytopenia (ITP) is a rare (orphan) blood disease. Most frequent manifestations of ITP are purpura, petechiae and bleedings with many patients have either no symptoms or minimal bleedings manifestation. The management of ITP varies widely and must be based on current international recommendations and individual assessment of clinical course. The paper presents the results of interim analysis of clinical course and therapeutic approaches in the Russian register of ITP patients with immune thrombocytopenia and literature review about ITP treatment approaches.